---
title: "UK Regulator OKs New Pneumonia, Meningitis Vaccine"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240496896.md"
description: "Merck Sharp & Dohme (UK)'s Capvaxive secured marketing authorization from the UK Medicines and Healthcare products Regulatory Agency as a vaccine against illnesses caused by bacteria called Streptococcus pneumoniae or pneumococcus. The vaccine, approved through the international recognition procedure, protects individuals aged 18 years and older against illnesses like pneumonia, meningitis and bacteraemia, according to a Thursday release. The agency noted it will keep the vaccine's safety and effectiveness under review."
datetime: "2025-05-16T04:15:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240496896.md)
  - [en](https://longbridge.com/en/news/240496896.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240496896.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/240496896.md) | [繁體中文](https://longbridge.com/zh-HK/news/240496896.md)


# UK Regulator OKs New Pneumonia, Meningitis Vaccine

Merck Sharp & Dohme (UK)'s Capvaxive secured marketing authorization from the UK Medicines and Healthcare products Regulatory Agency as a vaccine against illnesses caused by bacteria called Streptococcus pneumoniae or pneumococcus.

The vaccine, approved through the international recognition procedure, protects individuals aged 18 years and older against illnesses like pneumonia, meningitis and bacteraemia, according to a Thursday release.

The agency noted it will keep the vaccine's safety and effectiveness under review.

### Related Stocks

- [Merck & Co., Inc. (MRK.US)](https://longbridge.com/en/quote/MRK.US.md)
- [Definitive Healthcare Corp. (DH.US)](https://longbridge.com/en/quote/DH.US.md)
- [UnitedHealth Group Incorporated (UNH.US)](https://longbridge.com/en/quote/UNH.US.md)
- [Sharp Corporation (6753.JP)](https://longbridge.com/en/quote/6753.JP.md)

## Related News & Research

- [Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer](https://longbridge.com/en/news/281517399.md)
- [Infinimmune, Merck enter into antibody discovery pact](https://longbridge.com/en/news/281193725.md)
- [EU approves Merck Keytruda-paclitaxel regimen for PD-L1+ platinum-resistant ovarian cancer](https://longbridge.com/en/news/281509049.md)
- [GSK plc - ViiV completes changes to minority shareholding](https://longbridge.com/en/news/281310118.md)
- [Norfolk Southern Earnings Preview: What to Expect](https://longbridge.com/en/news/280999046.md)